Opinion|Videos|October 23, 2023
Mitigating Cardiovascular Risk In Obesity
Dhiren Patel, PharmD, and Bob Busch, MD, interview Fatima Cody Stanford, MD, MPH, MPA, an obesity medicine specialist, to examine the cardiovascular (CV) impact of obesity and delve into the potential benefits of newer weight loss medications in mitigating CV risk and heart failure.
Advertisement
Episodes in this series
1:14 Obesity and cardiovascular risk
3:28 Topline findings for semaglutide in the SELECT trial
7:15 CV risk reduction with semaglutide
8:54 Perspectives on cost-benefit for GLP-1 in obesity
14:14 Outcomes from STEP HFpEF trial
16:44 Considerations for using GLP-1 agonists
20:54 Need to address inequity in access to obesity medications
26:44 Investigational therapies for obesity with potential for CV benefits
30:00 Combination therapy for obesity and CV risk
Advertisement
Related to this article
Real-world COMPETE SWITCH CV data at EASD 2026 linked semaglutide 2 mg escalation to 6% lower MACE risk vs switching to tirzepatide in T2D.
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
EloraTZP cut body weight by up to 23.3% and A1C by up to 2.9% at 48 weeks vs 14.8% and 2.4% with tirzepatide 15 mg in a phase 2b trial.
Preview the biggest anticipated FDA decisions of Q4 2026, including bepirovirsen for CHB, obinutuzumab for pMN, bezuclastinib for systemic mastocytosis, and more.
Discover how newly cleared weekly basal insulin efsitora reshapes type 2 diabetes care—QWINT results, hypoglycemia edge, and dosing tips.
FDA approved mavacamten for oHCM in children weighing 30 kg or more after SCOUT-HCM showed a 48.0-mm Hg Valsalva LVOT gradient reduction vs placebo.
Jesus Almendral, MD, and Kanika Mody, MD, join the HCPLive team to discuss increases in hypertensive heart disease, heart failure, and other conditions.
Newly published results from the TRIUMPH-1 study have indicated the direct correlation between the triple agonist and several improvements to weight.
Advertisement
Advertisement
Trending on HCPLive
1
US Alcohol Use Falls, but Not for Adults Aged 50 to 64, With Brian Lee, MD
2
EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes
3
Nail Detachment 4 Times More Common With GLP-1 Use
4
FDA Approves Mavacamten for Pediatric Patients With Obstructive HCM
5